MAM
VYNE icon

Meeder Asset Management’s VYNE Therapeutics VYNE Stock Holding History

Meeder Asset Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-75
Closed -$15K – 2502
2020
Q1 		$15K Buy
75
+64
+582% +$20.1K ﹤0.01% 1365
2019
Q4 		$3K Sell
11
-1
-8% -$333 ﹤0.01% 1948
2019
Q3 		$4K Buy
12
+3
+33% +$968 ﹤0.01% 1837
2019
Q2 		$4K Sell
9
-4
-31% -$1.98K ﹤0.01% 1746
2019
Q1 		$7K Sell
13
-3
-19% -$1.44K ﹤0.01% 1330
2018
Q4 		$5K Buy
16
+4
+33% +$1.79K ﹤0.01% 1424
2018
Q3 		$9K Buy
+12
New +$7.41K ﹤0.01% 1194

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meeder Asset Management's VYNE Position: Q2 2020 in Review

Meeder Asset Management sold out of VYNE Therapeutics (VYNE) in Q2 2020, closing a stake of 75 shares — an estimated $15K sold.

Meeder Asset Management first reported a position in VYNE in Q3 2018 and held it in 7 quarters. The position peaked at $15K in Q1 2020. 106 funds tracked by Wall St. Rank hold VYNE as of Q2 2020.

  • Meeder Asset Management reported no remaining VYNE Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 75 VYNE Therapeutics shares in Q2 2020, an estimated $15K.
  • Meeder Asset Management first reported a position in VYNE Therapeutics in Q3 2018 and held it in 7 quarters.
  • Meeder Asset Management's VYNE Therapeutics position peaked at $15K in Q1 2020.
  • 106 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.